Market Cap (In EUR)
861.8 Million
Revenue (In EUR)
556.38 Million
Net Income (In EUR)
-545.06 Million
Avg. Volume
2917.00
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.33-23.93
- PE
- -4.92
- EPS
- -1.09
- Beta Value
- 2.088
- ISIN
- US6700024010
- CUSIP
- -
- CIK
- -
- Shares
- 160844000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John Charles Jacobs M.B.A.
- Employee Count
- -
- Website
- https://www.novavax.com
- Ipo Date
- 2001-02-01
- Details
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
More Stocks
-
4419King House CO., Ltd.
4419
-
UEPCPUnion Electric Company
UEPCP
-
YOKEF
-
4933
-
0QKURoyal Bank of Canada
0QKU
-
IMPC
-
SAH
-
FA